about
The established status epilepticus trial 2013.Epilepsy: recent advances.More than seizures: improving the lives of people with refractory epilepsy.Psychological treatments for functional non-epileptic attacks: a systematic review.Drug-induced status epilepticus.A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus.The effect of depression and side effects of antiepileptic drugs on injuries in patients with epilepsy.Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event?eLearning resources to supplement postgraduate neurosurgery training.Depression correlates with quality of life in people with epilepsy independent of the measures used.Clinical correlates of memory complaints during AED treatment.Different attachment styles correlate with mood disorders in adults with epilepsy or migraine.Screening of anxiety and quality of life in people with epilepsy.Screening for depression in epilepsy: a model of an enhanced screening tool.Non-hyperammonaemic valproate encephalopathy after 20 years of treatment.Which symptoms are indicative of depression in epilepsy settings? An analysis of the diagnostic significance of somatic and non-somatic symptoms.Medical student perceptions of clinical neurosurgery teaching in an undergraduate medical school curriculum.Subspecialty preferences among neurologists of the future.A case of de novo psychosis ten years following successful epilepsy surgery.Self-reported aggressiveness during treatment with levetiracetam correlates with depression.Vitamin D supplementation.Screening for depression in epilepsy clinics. A comparison of conventional and visual-analog methods.Learning from an exceptional boy.Understanding patient perceptions following a psycho-educational intervention for psychogenic non-epileptic seizures.Successful treatment of super-refractory tonic status epilepticus with rufinamide: First clinical report.Functional neurological disorders: acute presentations and managementValproate, women, and exceptional circumstancesValproate MHRA Guidance: Limitations and OpportunitiesHiding in Plain Sight: Functional Neurological Disorders in the NewsThe management of epilepsy during pregnancy--progress is painfully slowBrivaracetam in adults with drug-resistant epilepsy and psychiatric comorbiditiesLessons from the Established Status Epilepticus Treatment TrialEpilepsy deaths: Learning from health service delivery and trying to reduce riskMedical management of status epilepticus: Emergency room to intensive care unitA perspective on cannabinoids for treating epilepsy: Do they really change the landscape?Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment TrialSeizure-alerting behavior in dogs owned by people experiencing seizuresValproate and the Pregnancy Prevention Programme: exceptional circumstancesImplementing clinical guidelinesThe association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus
P50
Q30412553-429A02D1-75E0-47BE-BA85-2318C2E0D231Q37792844-9D6C71BD-D685-42AC-824E-A2E2C0BA4BB9Q38264833-E1E80C36-B676-4D0F-88E5-BBBD4EE4F007Q38266642-48A77C70-D2B4-4510-B8B3-E84E7D59E32DQ38554041-A1297B28-BA45-4E85-AA0A-E7495EAE4A61Q38580125-1C1FB045-0E4E-40C5-9A53-02431DA2380CQ38670342-87D26CB2-010C-4756-BABD-B7A977642F15Q38750672-EE6BB322-BD77-446F-897E-F4328A23EE61Q38786751-7E546D1A-735B-4CC3-A89B-1DE928717268Q39508230-C7685103-4C87-424D-B2FD-66549BB99C68Q40117991-8F3BA884-1DF4-401B-AF3D-9C7BCD1D7D14Q40171179-B43B3DDD-C3F0-44FA-9153-26D603E77221Q40421002-7BBA7C83-C9B3-4762-9123-E3EB7AEC833FQ41520591-5E9C66BF-E4D2-4A11-B5F8-0FB50C1B3075Q42016846-03D15456-A7C3-4013-AD22-84B538489169Q43974125-AC13BA08-0361-4631-BEF5-7FBCD46591E3Q47360031-B755D717-D622-4D71-82C8-DCFFFF4AAF01Q47386344-461CD776-1E0F-409F-9DB8-DC624259C50CQ47981589-6DB32A97-924B-4CF4-98A1-882CA7CCD2A9Q48086350-A1F33032-99EB-4BB0-9BF8-82CE85609AB1Q48292315-DD68130A-6846-4B3D-AA2B-172A2D47C905Q48650045-846266E1-1E7A-4D02-B07F-379073E53ADDQ50118942-117E620B-D212-4470-ABAE-61E8175AA9DBQ50588067-9CC36FDE-CF1D-48FA-A8C8-906496DE8B07Q53786757-0F73804B-F2D2-40E7-BAD4-A7EAC49BF3E7Q57053909-2395C29B-2E35-4303-8ADB-D346C8439E10Q60632468-B6AA8BB6-D132-4E12-B8CB-4F7A042460F1Q64230349-B582F7A9-791F-4B0F-B977-45AF8BD07A2CQ64764808-B6486F81-7523-40FC-99E4-C62AB0DFCE15Q84002334-6B566EAE-78D7-4F53-8DDB-55F7AD411681Q90361791-016321EC-1C47-41D0-88E4-3878D9E93401Q90949065-71DAB58F-0026-42A0-B633-DB6FC9E3C341Q91023524-C3D01D2E-9BDE-45D6-92C2-556154BEFA02Q91271088-A134906B-B83C-4E57-80A8-66675FF0919BQ91465372-D57BAC22-B597-4793-A4FE-638A09B1A956Q92508260-D5DB214F-14F2-4DE7-8561-CDA124279401Q92529228-57C7738A-AD38-4855-BAD5-D4DD015E2031Q92686921-C999DC65-88D4-452B-8A16-6CC4A832076FQ92689610-15CAEA41-6DDF-4670-A3B3-91C56F9A0B94Q95269680-89487327-6E88-4A1C-9354-EB22BD70F478
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hannah R Cock
@ast
Hannah R Cock
@en
Hannah R Cock
@es
Hannah R Cock
@nl
Hannah R Cock
@sl
type
label
Hannah R Cock
@ast
Hannah R Cock
@en
Hannah R Cock
@es
Hannah R Cock
@nl
Hannah R Cock
@sl
altLabel
H Cock
@en
H R Cock
@en
prefLabel
Hannah R Cock
@ast
Hannah R Cock
@en
Hannah R Cock
@es
Hannah R Cock
@nl
Hannah R Cock
@sl
P106
P21
P31
P496
0000-0002-5656-0141